Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAMAVAQ personalized neoantigen vaccine in newly diagnosed glioma
NCT07077616Phase 1Recruiting
- Sponsor
- Biogenea Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAMAVAQ NeoVaccine in glioma, sponsored by Biogenea Pharmaceuticals. Primary endpoints: TAMAVAQ Vaccine Safety Analysis at 28 weeks, Incidences of Adverse Events at 28 weeks and 4 more. Started Jul 2025; status: recruiting.
02
Drugs
TAMAVAQ NeoVaccine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07077616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077616.